Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00253617
First received: November 11, 2005
Last updated: April 2, 2013
Last verified: December 2006
  Purpose

RATIONALE: Stent placement may help reduce symptoms caused by the tumor. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for cholangiocarcinoma. It is not yet known whether stent placement and photodynamic therapy using porfimer sodium are more effective than stent placement alone in treating cholangiocarcinoma.

PURPOSE: This randomized phase III trial is studying stent placement and photodynamic therapy using porfimer sodium to see how well they work compared to stent placement alone as palliative treatment in treating patients with stage III or stage IV cholangiocarcinoma that cannot be removed by surgery.


Condition Intervention Phase
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Drug: porfimer sodium
Procedure: adjuvant therapy
Procedure: laser therapy
Procedure: photodynamic therapy
Procedure: phototherapy
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Enrollment: 0
Detailed Description:

OBJECTIVES:

Primary

  • Compare the overall survival time in patients with unresectable Bismuth type III or IV, stage III-IV cholangiocarcinoma treated with double plastic endoprostheses insertion with vs without adjuvant photodynamic therapy using porfimer sodium as palliative treatment.

Secondary

  • Compare the effect of these regimens on cholestasis in these patients.
  • Compare the 1-year survival rate in patients treated with these regimens.
  • Compare health-related quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are stratified according to participating center.

Patients undergo endoscopic or percutaneous drainage followed by insertion of bilateral plastic endoprostheses into the bile ducts. Patients are then randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive porfimer sodium IV on day 1. Patients undergo endoscopic laser light therapy to the tumor site on day 3.
  • Arm II: Patients receive no further treatment. Quality of life is assessed at baseline and then at weeks 2, 13, 26, 39, 52, and 65.

After completion of study treatment, patients are followed within 30-90 days.

PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed cholangiocarcinoma
  • Stage III or IV disease
  • Bismuth type III or IV disease
  • Tumor mass or stricture on cholangiogram and CT scan
  • Unresectable disease

PATIENT CHARACTERISTICS:

Performance status

  • Karnofsky 30-100%

Life expectancy

  • Not specified

Hematopoietic

  • WBC ≥ 2,000/mm^3
  • Platelet count ≥ 50,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Hematocrit ≥ 27%

Hepatic

  • PT or INR ≤ 2 times upper limit of normal (correctable with vitamin K)
  • No decompensated cirrhosis

Renal

  • Not specified

Other

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known porphyria or hypersensitivity to porphyrin
  • No clinically significant acute or chronic medial or psychological illness that would preclude study treatment
  • No other malignancy within the past 5 years except carcinoma in situ of the cervix or basal cell skin cancer
  • No concurrent untreated primary diagnosis of anxiety or depression

PRIOR CONCURRENT THERAPY:

Chemotherapy

  • More than 13 weeks since prior and no concurrent chemotherapy

Radiotherapy

  • More than 13 weeks since prior and no concurrent brachytherapy or radiotherapy

Surgery

  • No prior metal stent insertion
  • No prior surgical resection of cholangiocarcinoma

Other

  • No prior photodynamic therapy for this disease
  • More than 60 days since prior investigational drugs
  • No concurrent administration of the following:
  • Ursodiol
  • Herbal products that may increase bile flow, including any of the following:
  • Andrographis paniculata
  • Chelidonium majus L
  • Curcumin L
  • Cynara scolymus L (artichoke)
  • Gentiana lutea
  • Mentha x piperita (peppermint)
  • Peumus boldus Mol
  • Taraxacum officinale (dandelion)
  • No administration of any of the following within 7 days of porfimer sodium injection:
  • Supplements in vitamins C, E, and β-carotene
  • Camellia sinensis (green tea)
  • Silymarin
  • EGb761
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00253617

Locations
United States, California
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781
Canada, Quebec
Axcan Pharma, Incorporated
Mont-Saint-Hilaire, Quebec, Canada, J3H 6C4
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Study Chair: James Farrell, MD Jonsson Comprehensive Cancer Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00253617     History of Changes
Other Study ID Numbers: AXCAN-PHOCCC04-01, UCLA-0501033-01, CDR0000449701
Study First Received: November 11, 2005
Last Updated: April 2, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Gallbladder Neoplasms
Bile Duct Neoplasms
Cholangiocarcinoma
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Biliary Tract Diseases
Digestive System Diseases
Gallbladder Diseases
Bile Duct Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Trioxsalen
Dihematoporphyrin Ether
Photosensitizing Agents
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 30, 2014